following a full submission under the end of life and orphan equivalent process:
nintedanib (Vargatef®) is accepted for use within NHS Scotland.
Indication under review: in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Addition of nintedanib to second-line treatment of stage IIIb/IV NSCLC with docetaxel significantly increased overall survival in the subgroup patients with adenocarcinoma tumour histology.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of nintedanib and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice166KB (PDF)
Medicine details
- Medicine name:
- nintedanib (Vargatef)
- SMC ID:
- 1027/15
- Indication:
- In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2015